• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

    36.31 +0.01 (+0.03%)
    Streaming Delayed Price Updated: 12:53 PM EDT, Aug 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,173,355
    Open 36.22
    Bid (Size) 36.30 (200)
    Ask (Size) 36.32 (300)
    Prev. Close 36.30
    Today's Range 35.70 - 36.48
    52wk Range 11.60 - 37.97
    Shares Outstanding 692,072,184
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Roivant Sciences Q1 Earnings Call Highlights ↗
    Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions... 
    Via MarketBeat
    Topics Earnings Government
    News headline image
    Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire

    Performance

    YTD
    +65.6%
    +65.6%
    1 Month
    +3.7%
    +3.7%
    3 Month
    +22.4%
    +22.4%
    6 Month
    +30.8%
    +30.8%
    1 Year
    +211.9%
    +211.9%

    More News

    Read More
    News headline image
    Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
    From Roivant Sciences
    Via GlobeNewswire
    ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗
    Via Chartmill
    News headline image
    Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗
    Via The Motley Fool
    News headline image
    Roivant (ROIV) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Roivant Sciences Q4 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings Government
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
    Via The Motley Fool
    News headline image
    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
    Via The Motley Fool
    News headline image
    Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire

    Frequently Asked Questions

    Is Roivant Sciences Ltd. - Common Shares publicly traded?
    Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
    What exchange does Roivant Sciences Ltd. - Common Shares trade on?
    Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
    The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
    What is the current price of Roivant Sciences Ltd. - Common Shares?
    The current price of Roivant Sciences Ltd. - Common Shares is 36.31
    When was Roivant Sciences Ltd. - Common Shares last traded?
    The last trade of Roivant Sciences Ltd. - Common Shares was at 08/24/26 12:53 PM ET
    What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
    The market capitalization of Roivant Sciences Ltd. - Common Shares is 25.13B
    How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
    Roivant Sciences Ltd. - Common Shares has 25B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.